Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced successful mapping of the ...

The medicines regulator has flagged up a small increased risk of Guillain-Barré syndrome after RSV vaccination in adults over ...

Enanta’s reliance on partnerships for the further development of its antiviral treatments, particularly in the RSV space, presents a potential risk to the company’s growth trajectory.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a biotechnology company specializing in small molecule drugs for viral infections and liver diseases, is undergoing a strategic shift towards immunology ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a biotechnology company specializing in small molecule drugs for viral infections and liver diseases, is undergoing a strategic shift towards immunology ...

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.

FDA approves ENFLONSIA, a long-acting monoclonal antibody to protect infants from RSV-related lung disease through their first winter with a single fixed-dose shot.

Whitney Hamilton says her 4-year-old son, Elijah, is always happy, but his life dramatically changed in February 2024 when he developed a devastating brain condition that stemmed from the flu.